Results 171 to 180 of about 10,491 (187)

Clinical Pharmacology Profile of Raltegravir, an HIV-1 Integrase Strand Transfer Inhibitor

Journal of Clinical Pharmacology, 2011
Larissa A Wenning, Julie A Stone
exaly  

Lack of a Clinically Meaningful Pharmacokinetic Effect of Rifabutin on Raltegravir: In Vitro/In Vivo Correlation

Journal of Clinical Pharmacology, 2011
Larissa A Wenning, Julie A Stone
exaly  

Hydroxyl may not be indispensable for raltegravir: Design, synthesis and SAR Studies of raltegravir derivatives as HIV-1 inhibitors

European Journal of Medicinal Chemistry, 2012
Ziwen Wang, Xue Yao, Yue Li
exaly  

Raltegravir

Reactions Weekly, 2011
openaire   +2 more sources

New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors

Journal of Antimicrobial Chemotherapy, 2014
Isabelle Malet, Anna Artese, Giosuè Costa   +2 more
exaly  

Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients

Pharmacological Research, 2012
Dario Cattaneo, Cristina Gervasoni, Valeria Cozzi   +2 more
exaly  

Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography–tandem mass spectrometric method

Journal of Mass Spectrometry, 2011
Lingzhi Wang, Lawrence S Lee, Edmund Jon Deoon Lee   +2 more
exaly  

Raltegravir: the first HIV‐1 integrase strand transfer inhibitor in the HIV armamentarium

Annals of the New York Academy of Sciences, 2011
Bach-Yen T Nguyen, Hedy Teppler, Randi Y Leavitt   +2 more
exaly  

Raltegravir

Reactions Weekly
openaire   +1 more source

Lack of specificity for the analysis of raltegravir using online sample clean-up liquid chromatography–electrospray tandem mass spectrometry

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009
Françoise Stanke-Labesque
exaly